GeoVax Labs, Inc.
1900 Lake Park Drive, Suite 380
Smyrna, GA 30080

You Might Also Like...

Key Points About GeoVax

Blogs: GOVX

Recent News Releases

GeoVax Reports Promising Results for Lassa Fever Vaccine

GeoVax Labs, Inc. , a biotechnology company developing human vaccines, announced today a significant step forward in the development of a vaccine candidate for protection against Lassa hemorrhagic...Read more

GeoVax Awarded NIH Grant for Zika Vaccine

GeoVax Labs, Inc. , a biotechnology company developing innovative human vaccines, announced today that the National Institute of Allergy and Infectious Diseases , part of the National Institutes of...Read more

GOVX: Update on First Quarter Financials

By Grant Zeng, CFA OTC:GOVX Net revenues for the 1Q17 ended March 31, 2017 were $295,735, which related to grants from the NIH. This compared to $47,600 of grant revenues reported for the same period...Read more

GeoVax to Conduct Partnering Meetings During BIO International Convention June 19-22

GeoVax Labs, Inc. , a biotechnology company developing human vaccines, announced today that it is scheduling corporate partnering meetings during the BIO International Convention, to be held in San...Read more

GeoVax Labs, Inc. (GOVX-OTC)

GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a clinical-stage biotechnology company developing preventative and therapeutic human vaccines against infectious diseases and cancer. The Company’s unique and patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) technology is the foundation for producing non-infectious virus-like particles (VLPs) from the cells of the individual receiving the vaccine. Producing VLPs in a vaccinated person mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear, while maintaining the safety characteristics of a replication-defective vector. GeoVax is currently focused on developing vaccines against human immunodeficiency virus (HIV), Zika virus (ZIKV), hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa), and malaria. The Company also has programs to develop a vaccine to treat chronic Hepatitis B virus (HBV) infection and to apply its MVA-VLP technology to cancer immunotherapy (immuno-oncology). GeoVax believes its technology and development expertise is complementary to a range of other human diseases for which there is an unmet medical need, and accordingly, has plans to expand its pipeline.

* The Corporate Snapshot was last updated on June 19, 2017.

Latest Research


Download GeoVax Report 


Key Points About GeoVax

Blogs: GOVX